Alamar Biosciences (ALMR) 10% Owner Ltd. Sells $6.3M of Stock
Key Points
- Ten percent owner Qiming Corporate GP VI, Ltd. sold 208,815 shares of Alamar Biosciences, Inc. on October 21, 2026, for roughly $6.3 million.
- After the trade, Qiming Corporate GP VI, Ltd. indirectly holds 1,813,462 $ALMR shares, down 10.33% from before the trade.
- Alamar Biosciences recently traded around $30.69, sitting below its 50-day moving average but well above its 200-day moving average.
- Major institutional funds including Sands Capital Alternatives and Samsara BioCapital hold large stakes in the proteomics company.
Since the trade, $ALMR is down 5.5% to date (from the $31.45 close on Oct 21, 2026).
Get Alamar Biosciences text alerts
We text you when insiders, Congress, analysts or big funds move on $ALMR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Alamar Biosciences, Inc. alert may contain errors. Disclosures
Major shareholder Qiming Corporate GP VI, Ltd. sold 208,815 shares of Alamar Biosciences, Inc. ticker ALMR on October 21, 2026. The transaction was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission.
ALMR
Alamar Biosciences, Inc.
Inside Qiming Corporate GP VI's Alamar Biosciences Trade
According to the SEC filing, the 10% owner sold the shares at an average price of $30.31 for a total value of $6,328,765.02. Following the transaction, the entity held 1,813,462 shares, representing a 10.33% reduction in its position. This transaction follows several earlier sales by the same owner in October 2026.
Other Institutional Activity in Alamar Biosciences
Other large funds hold substantial positions in the company. Sands Capital Alternatives, LLC grew its holdings by 2,115,463 shares, ending with 4,230,926 shares worth about $129,847,121. Samsara BioCapital, LLC grew its holdings by 1,240,155 shares, ending with 2,480,310 shares worth about $76,120,715. ARK Investment Management, LLC grew its holdings by 686,980 shares, ending with 1,373,959 shares worth about $42,166,802. Braidwell LP grew its holdings by 541,992 shares, ending with 1,083,983 shares worth about $33,267,438. Alliancebernstein L.P. grew its holdings by 501,538 shares, ending with 1,003,077 shares worth about $30,784,433.
Alamar Biosciences, Inc. Stock Down 2.4%
Alamar Biosciences shares recently traded around $30.69 as of October 24, 2026, down about 2.4% from the $31.45 close on the day of the trade. The stock sits slightly below its 50-day moving average of $30.84 but remains roughly 15.0% above its 200-day moving average of $26.69. Over the past year, the shares have traded between a low of $18.85 and a high of $39.61.
Recent Earnings
For the trailing twelve months, Alamar Biosciences reported $100,420,000 in revenue and basic earnings per share of -$1.2. The company is scheduled to release its next financial results on November 3, 2026.
Insider Buying and Selling at Alamar Biosciences, Inc.
The company experienced multiple insider transactions prior to this event, including sales by Qiming Corporate GP VI and a purchase by Director Nicholas J. Naclerio.
Analysts Set New Price Targets
Wall Street analysts maintain positive views on the stock, with firms such as Stifel and JP Morgan issuing ratings ahead of the upcoming earnings report.
About Alamar Biosciences
Alamar Biosciences, Inc. is a Fremont, California-based medical device company specializing in proteomics. The firm develops liquid biopsy platforms, including its proprietary NULISA technology, which helps detect and quantify protein biomarkers for early disease detection. The company employs 286 people and serves the healthcare sector.
Bottom Line
Investors are keeping an eye on Alamar Biosciences as the company approaches its next earnings announcement on November 3, 2026. Further regulatory filings will show whether major shareholders continue adjusting their positions.
Related Filing Alerts
Source: Qiming Corporate GP VI, Ltd.'s Form 4 filing on $ALMR (Oct 21, 2026). Written by software, not financial advice. How we make alerts